Routine invasive management early after fibrinolysis: Relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trials Akshay Bagai, MD, MHS, Mary Tan, MSc, Carlo Di Mario, MD, Sigrun Halvorsen, MD, PhD, Warren J. Cantor, MD, Michel R. Le May, MD, Francisco Fernandez-Aviles, MD, Bruno Scheller, MD, Paul W. Armstrong, MD, Francesco Borgia, MD, Federico Piscione, MD, Pedro L. Sánchez, MD, Cynthia M. Westerhout, PhD, Shaun G. Goodman, MD, MSc, Andrew T. Yan, MD American Heart Journal Volume 168, Issue 5, Pages 757-765.e3 (November 2014) DOI: 10.1016/j.ahj.2014.07.027 Copyright © 2014 Elsevier Inc. Terms and Conditions
Figure 1 Kaplan-Meier curves for 30-day outcomes. A, Kaplan-Meier curves for death/re-MI at 30days. B, Kaplan-Meier curves for death at 30days. C, Kaplan-Meier curves for re-MI at 30days. American Heart Journal 2014 168, 757-765.e3DOI: (10.1016/j.ahj.2014.07.027) Copyright © 2014 Elsevier Inc. Terms and Conditions
Figure 2 Treatment effect of routine early invasive strategy in relation to baseline risk stratified by trial. There was no heterogeneity in treatment efficacy by baseline risk observed across the individual trials (P for interaction=.91). American Heart Journal 2014 168, 757-765.e3DOI: (10.1016/j.ahj.2014.07.027) Copyright © 2014 Elsevier Inc. Terms and Conditions